@article{de3b3c261cd04938b9bab9353d1aba19,
title = "PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation",
abstract = "Monoclonal antibodies that target the programmed death-1 (PD-1)-programmed death ligand-1 (PD-L1) axis have antitumor activity against multiple cancers. The presence of sarco-matoid differentiation in renal cell carcinoma (RCC) is associated with resistance to targeted therapy and poor responses to IL2 immunotherapy. Given the aggressive nature of RCC with sarco-matoid differentiation and the exclusion of sarcomatoid histology from metastatic RCC clinical trials, less is understood regarding selection of therapies. Here, we characterized the PD-1/PD-L1 axis in RCC with sarcomatoid differentiation. We directly compared two PD-L1 antibodies and found concordance of PD-L1 positivity in 89% of tested RCCs with sarcomatoid differentiation. Coexpression of PD-L1 on neoplastic cells and the presence of PD-1-positive tumor-infiltrating lymphocytes were identified in 50% (13 of 26) of RCCs with sarcomatoid differentiation. In contrast, only 1 of 29 clear cell RCCs (3%) had concurrent expression of PD-L1 and PD-1 (P = 0.002). Our study suggests that RCC with sarcomatoid differentiation may express PD-1/PD-L1 at a higher percentage than RCC without sarcomatoid differentiation, and patients with these tumors may be good candidates for treatment with anti-PD-1/PD-L1 therapies.",
author = "Joseph, {Richard W.} and Millis, {Sherri Z.} and Carballido, {Estrella M.} and David Bryant and Zoran Gatalica and Sandeep Reddy and Bryce, {Alan H.} and Vogelzang, {Nicholas J.} and Stanton, {Melissa L.} and Castle, {Erik P.} and Ho, {Thai H.}",
note = "Funding Information: Grant Support The work was supported by the Gloria A. and Thomas J. Dutson Jr, Kidney Research Endowment (Mayo Clinic). This project was supported in part by funding from the Center for Individualized Medicine (CIM). T.H. Ho is supported by funding from the ASCO Young Investigator Award from the Kidney Cancer Association, the Action to Cure Kidney Cancer, a Kathryn H. and Roger Penske Career Development Award to Support Medical Research, a Gerstner Family Foundation Career Development Award, and a U.S. NIH grant (K12CA90628). R.W. Joseph is supported by a grant from the American Association for Cancer Research and the Mayo Clinic Center for Individualized Medicine established through a gift from the Gerstner Family. This publication was made possible by CTSA grant number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Publisher Copyright: {\textcopyright} 2015 American Association for Cancer Research.",
year = "2015",
month = dec,
doi = "10.1158/2326-6066.CIR-15-0150",
language = "English (US)",
volume = "3",
pages = "1303--1307",
journal = "Cancer Immunology Research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "12",
}